Nutraceuticals and Functional Foods in Canada: How Health Canada Decides If Your Product Is an NHP, a Drug, or a Food

A supplement brand based in Calgary came to us last spring with what seemed like a simple question: their new omega-3 enriched sparkling water was going to market in two months. Did they need an NPN, or was it just a food product? The answer involved four different regulatory documents, a conversation with Health Canada’s classification team, and ultimately a label redesign. Two months became six.

That story isn’t unusual. The confusion around nutraceuticals and functional foods in Canada is structural — baked into the regulatory framework itself. Canada has no formal “nutraceutical” category. It doesn’t exist in the Food and Drug Act, the Natural Health Products Regulations (NHPR), or any Health Canada guidance document. What Canada does have is a three-way split between foods, natural health products, and drugs — and where your product lands determines everything from your labelling obligations to whether you need a site licence before you can manufacture it.

Canada Has No “Nutraceutical” Category — Here’s What That Actually Means

The word “nutraceutical” blends “nutrition” and “pharmaceutical.” It’s useful marketing language. It has never appeared in a Canadian statute.

This creates a structural problem for manufacturers. A plant sterol-enriched margarine, a probiotic capsule, a high-dose vitamin D supplement, and a melatonin gummy might all be described as nutraceuticals in a trade publication. Under Canadian law, each falls into a completely different regulatory category with completely different obligations.

Health Canada classifies every health and food product as one of three things:

• Food: consumed for taste, aroma, or nutritive value. Governed by the Food and Drug Regulations (FDR).
• Natural Health Product (NHP): a naturally-occurring substance used to maintain or improve health. Governed by the NHPR (SOR/2003-196). Requires a product licence and an NPN before sale.
• Drug: used to diagnose, treat, mitigate, prevent, or cure a disease or condition. Requires a Drug Identification Number (DIN) under Division 1 of the FDR.

What determines the classification isn’t just ingredients. It’s a combination of format, intended use, label claims, and concentration. Change any one of those variables and you may change your regulatory pathway entirely.

What the NHPR Actually Defines as a Natural Health Product

The Natural Health Products Regulations, which came into force in January 2004 and are registered as SOR/2003-196, define “natural health product” in Section 1 as a substance set out in Schedule 1, a combination of those substances, a homeopathic medicine, or a traditional medicine — manufactured, sold, or represented as suitable for maintaining or improving health, preventing or treating a disease, or restoring organic function.

Schedule 1 is the substance list that determines eligibility. It includes:

• Plant material, algae, bacteria, fungi, and non-human animal material
• Extracts or isolates of the above, where the molecular structure doesn’t significantly change during processing (or changes to produce a substance with a similar chemical structure)
• Vitamins, minerals, amino acids, and essential fatty acids
• Synthetic duplicates of Schedule 1 substances

That last point catches many manufacturers off guard. A synthesized vitamin B12 qualifies as an NHP even though it’s manufactured identically to a pharmaceutical-grade ingredient. Substance identity matters more than manufacturing origin.

Since January 2004, Health Canada has issued more than 90,000 NPNs — covering everything from echinacea extracts to high-potency fish oil to melatonin. Melatonin is a useful reference case. It’s sold over the counter without restriction in the United States, but in Canada it’s classified as an NHP that requires a product licence. Daily doses above 10 mg per serving are subject to additional clinical evidence requirements. Same molecule, entirely different regulatory journey depending on which side of the border you’re manufacturing on.

Functional Foods and Fortified Foods: Where the Lines Actually Sit

Canada doesn’t have a formal “functional food” category, but the FDR does explicitly permit fortification of specific foods under Division 5. Table XII of Division 5 sets maximum permitted levels for vitamins and minerals in products like flour, cornmeal, and breakfast cereals. These are foods. No NPN is required, no site licence is needed, and manufacturers aren’t held to the NHP quality system standard under Part 3 of the NHPR.

Novel foods are a separate category under Division 28 of the FDR — foods derived from new sources, new manufacturing processes, or significant genetic or molecular modification. A beverage fermented with a bacterial culture not previously used as a food source may require a pre-market novel food notification before it can be sold. Simple submissions typically resolve within 45 days. Complex submissions, particularly those involving biotechnology-derived ingredients, take considerably longer.

The overlap with NHPs happens reliably in three scenarios:

Format signals “supplement,” not “food.” Products structured like daily doses — single-serve sachets, capsule-in-water sticks, effervescent tablets, dropper bottles — tend to be classified as NHPs regardless of the underlying ingredients. The presentation implies supplementation, not eating.

Claims shift the classification. A plain probiotic yogurt is food. The same yogurt with “supports digestive balance” or “promotes healthy gut flora” on the label is making a health claim that Health Canada associates with natural health products. The formulation hasn’t changed. The regulatory category has. Health Canada’s guidance on NHP labelling and claims defines the distinction clearly, and inspectors apply it consistently.

Therapeutic concentrations change the analysis. A low-dose omega-3 addition to a fortified food at levels permitted under Division 5 remains food. The same fatty acid in a 2,000 mg softgel marketed for cardiovascular support is an NHP. Concentration matters, and the NHP framework is specifically designed to accommodate bioactive substances at doses that have a measurable physiological effect.

How to Get a Classification Decision Before You Launch

Health Canada has a formal mechanism for resolving classification questions before a product reaches market. Requests go through the Natural and Non-prescription Health Products Directorate (NNHPD), which administers the NHPR and can provide written decisions on whether a product falls under the FDR or the NHPR.

A useful classification submission includes: a complete ingredient list with quantitative composition per daily dose, intended use statements and any proposed label claims, the product format and delivery mechanism, and any existing regulatory status in comparable markets — the Australian TGA, the US FDA, or the EU — that might provide useful context. Health Canada isn’t bound by those foreign determinations, but they do inform the analysis.

Written classification decisions don’t come on a fixed timeline, but in our experience most straightforward cases resolve within 8–12 weeks. For genuinely ambiguous products — a high-potency fermented botanical extract in a shot format, say — that written decision is worth every week of waiting. It removes the jurisdictional question before you build your quality documentation, finalize your label, or apply for a site licence under Part 2 of the NHPR.

Once classified as an NHP, the product licence application is tiered by risk. Class I products (well-established, low-risk formulations with compendial support) carry a 60-day review target. Class II applications target 180 days. Class III applications — complex formulations, new substances, or products with novel health claims — can run up to 300 days under Health Canada’s stated service standards. Actual review times frequently exceed these targets, which makes early classification resolution even more valuable: you can prepare your licence application in parallel with the classification review rather than waiting on both sequentially.

The Cost of Getting the Classification Wrong Goes Both Ways

Selling a product that should be licensed as an NHP without holding a product licence violates Section 4 of the NHPR, which prohibits sale of an NHP without a licence. Enforcement consequences range from a written warning requiring product removal to formal seizure under Section 23 of the Food and Drugs Act. Health Canada’s Health Products and Food Branch (HPFB) inspectors actively monitor online marketplaces and import shipments — and misclassified products in those channels are caught with regularity.

But misclassification runs in the other direction too. A manufacturer who spends 12–18 months obtaining an NPN for a product that Health Canada would have classified as a fortified food has delayed market entry unnecessarily and built a GMP quality system — with all its documentation, personnel, and audit burden — around requirements that didn’t apply. Both errors cost real money. The early classification request costs almost nothing in comparison.

There’s also a strategic dimension that’s worth naming. Many brands assume NHP classification is the less desirable outcome because it adds regulatory burden. That’s not always accurate. An NPN permits health claims on labels that are prohibited for food products under Section 5 of the Food and Drugs Act. If your product’s value proposition depends on communicating a specific health benefit, the NHP pathway isn’t a burden — it may be the only pathway that lets you say what you need to say to your customer.

The Practical Starting Point

If your product contains a Schedule 1 substance in concentrated form, makes any health maintenance or disease-prevention claim, or is packaged and presented like a daily dose supplement, assume it requires a product licence under Canada’s natural health products regulations and work backwards from there. If it’s genuinely ambiguous — and in many cases it is — request a formal classification decision from the NNHPD before finalizing your label or your site’s quality management structure.

The classification question isn’t a minor administrative detail you can sort out after launch. It determines which federal act governs your product, which inspections apply to your manufacturing site, what claims are lawful on your packaging, and what a compliance officer will do if your label doesn’t align with your licence status. Getting that question answered clearly, in writing, at the start of development is one of the few decisions in Canadian regulatory affairs that has no real downside.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance. Contact us

Related from our network

• Supplement and NHP Testing for the US Market — ISO 17025-accredited analytical testing for supplement manufacturers seeking FDA compliance documentation and retailer program qualification in the United States.
• EU Novel Food and Natural Health Product Regulatory Pathways — Expert guidance on EU 2015/2283 Novel Food regulation and health claim frameworks for Canadian brands expanding into European markets.